These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of nifedipine in rats: Possible role of P-gp and CYP3A4 inhibition by HMG-CoA reductase inhibitors. Lee CK; Choi JS; Choi DH Pharmacol Rep; 2015 Feb; 67(1):44-51. PubMed ID: 25560574 [TBL] [Abstract][Full Text] [Related]
8. The role of cytochrome P450-mediated drug-drug interactions in determining the safety of statins. Worz CR; Bottorff M Expert Opin Pharmacother; 2001 Jul; 2(7):1119-27. PubMed ID: 11583063 [TBL] [Abstract][Full Text] [Related]
9. Rhabdomyolysis after concomitant use of cyclosporine, simvastatin, gemfibrozil, and itraconazole. Maxa JL; Melton LB; Ogu CC; Sills MN; Limanni A Ann Pharmacother; 2002 May; 36(5):820-3. PubMed ID: 11978159 [TBL] [Abstract][Full Text] [Related]
10. Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics. Neuvonen PJ Curr Opin Investig Drugs; 2010 Mar; 11(3):323-32. PubMed ID: 20178046 [TBL] [Abstract][Full Text] [Related]
11. Rhabdomyolysis with HMG CoA reductase inhibitors: a class effect? Langford NJ; Kendall MJ J Clin Pharm Ther; 2001 Dec; 26(6):391-5. PubMed ID: 11722675 [No Abstract] [Full Text] [Related]
12. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Transon C; Leemann T; Dayer P Eur J Clin Pharmacol; 1996; 50(3):209-15. PubMed ID: 8737761 [TBL] [Abstract][Full Text] [Related]
13. Statin safety: a systematic review. Law M; Rudnicka AR Am J Cardiol; 2006 Apr; 97(8A):52C-60C. PubMed ID: 16581329 [TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Lennernäs H; Fager G Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173 [TBL] [Abstract][Full Text] [Related]
15. Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Cohen LH; van Leeuwen RE; van Thiel GC; van Pelt JF; Yap SH Biopharm Drug Dispos; 2000 Dec; 21(9):353-64. PubMed ID: 11523064 [TBL] [Abstract][Full Text] [Related]
16. HMG-CoA reductase inhibitors: assessing differences in drug interactions and safety profiles. Beaird SL J Am Pharm Assoc (Wash); 2000; 40(5):637-44. PubMed ID: 11029845 [TBL] [Abstract][Full Text] [Related]
17. Co-administration of statins with cytochrome P450 3A4 inhibitors in a UK primary care population. Bakhai A; Rigney U; Hollis S; Emmas C Pharmacoepidemiol Drug Saf; 2012 May; 21(5):485-93. PubMed ID: 22237927 [TBL] [Abstract][Full Text] [Related]